XERS Share Price Performance
US$8.34
3.23 (63.21%)
51.6% undervalued intrinsic discount
US$17.23
Fair Value
Price US$8.34
AnalystHighTarget US$17.23
AnalystConsensusTarget US$11.14
AnalystLowTarget US$8.00
Fair ValueUS$17.23
Share Pricen/a
Xeris Biopharma Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
XERS Community Narratives
AN
Fair Value
·Fair Value US$17.23 51.6% undervalued intrinsic discount
Rising Global Chronic Illness Will Drive Self-Administered Endocrine Therapies Expansion
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value US$11.14 25.2% undervalued intrinsic discount
XERS: Higher 2025 Revenue Guidance Will Drive Measured Financial Outlook
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value
·Fair Value US$8 4.3% overvalued intrinsic discount
Rising Healthcare Costs And Regulation Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Healthcare Costs And Regulation Will Erode Margins
Xeris Biopharma relies heavily on a small set of medicines, and rising healthcare costs and tougher scrutiny from insurers and regulators could make it harder to keep prices and expand as planned. At the same time, strong recent sales, a key new drug in development, and partnerships built around its formulation technology could still push the business toward steady growth and better profits.Read more
AN
US$8
4.3% overvalued intrinsic discount
Fair Value
Revenue
20.87% p.a.
Profit Margin
13.95%
Future PE
26.61x
Price in 2029
US$9.78
Rising Global Chronic Illness Will Drive Self-Administered Endocrine Therapies Expansion
Key Takeaways Xeris is positioned for rapid earnings growth and margin expansion due to strong product adoption, innovative pipeline, and operational discipline in underserved endocrine markets. Structural healthcare trends and new commercial channels could unlock substantial long-term revenue streams and support accelerated market share gains.Read more
AN
US$17.23
51.6% undervalued intrinsic discount
Fair Value
Revenue
27.28% p.a.
Profit Margin
27.17%
Future PE
27.22x
Price in 2029
US$21.07
XERS: Higher 2025 Revenue Guidance Will Drive Measured Financial Outlook
Key Takeaways Strong demand for key therapies and strategic investments in commercialization and partnerships are expected to drive sustained revenue growth and operational leverage. Expansion into underserved markets and focus on innovation position the company to capture new revenue streams and support long-term profit margin improvement.Read more
AN
US$11.14
25.2% undervalued intrinsic discount
Fair Value
Revenue
22.77% p.a.
Profit Margin
19.17%
Future PE
27.81x
Price in 2029
US$13.63
Trending Discussion
Recently Updated Narratives
AN
XERS: New Patent Protection Will Support Stronger Medium Term Cash Expectations
Fair Value: US$8 4.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
XERS: 2026 Revenue Outlook Will Support Stronger Future Cash Generation
Fair Value: US$17.23 51.6% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
XERS: Higher 2025–2026 Revenue Guidance Will Support Future Cash Generation
Fair Value: US$11.14 25.2% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Xeris Biopharma Holdings, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- 0.07
- 85.89%
- 3.81%
- 1,700.3%
About XERS
- Founded
- 2005
- Employees
- 435
- CEO
- WebsiteView website
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
